[go: up one dir, main page]

EP2344173A1 - Nouvelle association synergique pour le traitement de lésions profondes de la peau ou des muqueuses - Google Patents

Nouvelle association synergique pour le traitement de lésions profondes de la peau ou des muqueuses

Info

Publication number
EP2344173A1
EP2344173A1 EP08875210A EP08875210A EP2344173A1 EP 2344173 A1 EP2344173 A1 EP 2344173A1 EP 08875210 A EP08875210 A EP 08875210A EP 08875210 A EP08875210 A EP 08875210A EP 2344173 A1 EP2344173 A1 EP 2344173A1
Authority
EP
European Patent Office
Prior art keywords
extract
skin
injuries
growth
synergistic composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08875210A
Other languages
German (de)
English (en)
Inventor
Ravishekhar Shrivastava
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Naturveda
Original Assignee
Naturveda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naturveda filed Critical Naturveda
Publication of EP2344173A1 publication Critical patent/EP2344173A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Definitions

  • Fibroblasts are the major cells for the production of tropocollagen, collagen, elastin, and proteoglycans that makes up the intercellular matrix. In this way fibroblast cells prepare a ground for their own future growth. During healing, the fibroblast cells located in the deeper part start growing, and reach up to the level of dermis. At this stage, the fibroblasts secrete EGF and keratinocyte growth factor (KGF) which sparks the growth of skin epithelial cells to close the injury. The primary reduction in the depth of the injury is due to the growth of deeper fibroblast cells followed by the growth of superficial epithelial cells to complete the healing process.
  • KGF keratinocyte growth factor
  • an ideal product should be easy to apply, should be colourless so as to avoid daily injury cleaning, should be capable to adhere to the injury surface, should neutralise infection whether of bacterial or viral origin, should be of natural origin if possible so as to avoid cytotoxicity, should not be irritant and should not contain alcohol or chemicals which interfere with the cell growth.
  • Another objective of the present invention is to provide a synergistic composition for the treatment of bedsore, pressure ulcers and diabetic ulcers as well as the skin injuries involving improper functioning of cutaneous or the subcutaneous tissues and injuries of viral origin.
  • echinacosides is intended to mean the water soluble polysaccharide fraction in the extract.
  • the synergistic compositions according to the invention can comprise said plant extract(s) and said injury healing agent(s) in a molar ratio between 10/1 and 1/10.
  • injury is intended to mean any damage or harm done to the skin or the mucus membrane in which the skin or mucus membrane is broken, cut, pierced, torn or damaged.
  • Injury can be traumatic, non-traumatic, of infectious origin, of non infectious origin.
  • the present invention also relates to the non-therapeutic use of a synergistic composition according to the invention for promoting the growth of fibroblast and epithelial cells.
  • 3xlO 5 cells were initially seeded in lOO ⁇ l culture medium (MEM) with 10% foetal calf serum (FCS) in 96 well tissue culture plates (Corning, USA) for 24h in a 5% CO2 - 37°c environment. After 24h, initial medium was replaced by a new medium containing lOO ⁇ l fresh growth medium (2% FCS) containing appropriate concentration of the test product (plant extract) was added to each culture well. Cells were incubated for further 48h and cell number was measured using MTT vital stain. 24 wells were used for each experiment with corresponding untreated controls and experiments were repeated at least 3 times.
  • MEM lOO ⁇ l culture medium
  • FCS foetal calf serum
  • the injured area of the back was then covered with a 8-layered sterile bandage which was loosely secured by adhesive tape. The same procedure was repeated every day for 12 consecutive days.
  • the mean diameter of lesions (mm) was as follows:
  • the BCOP Bovine Corneal Ocular Irritation in vitro test classify all the products as slightly irritant. II.7. Stability tests

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition synergique comprenant au moins deux composés choisis dans le groupe comprenant : - un extrait d’Alchemilla vulgaris ; - un extrait de Mimosa tenuiflora ; et – un extrait d’Echinacea purpurea. Elle concerne en outre un médicament comprenant ladite composition synergique pour le traitement de lésions de la peau ou des muqueuses, en particulier des lésions profondes de la peau ou des muqueuses, et un procédé pour favoriser la croissance de fibroblastes et de cellules épithéliales, comprenant l’étape consistant à administrer à un sujet ladite composition synergique.
EP08875210A 2008-10-21 2008-10-21 Nouvelle association synergique pour le traitement de lésions profondes de la peau ou des muqueuses Withdrawn EP2344173A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2008/064214 WO2010045969A1 (fr) 2008-10-21 2008-10-21 Nouvelle association synergique pour le traitement de lésions profondes de la peau ou des muqueuses

Publications (1)

Publication Number Publication Date
EP2344173A1 true EP2344173A1 (fr) 2011-07-20

Family

ID=40013722

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08875210A Withdrawn EP2344173A1 (fr) 2008-10-21 2008-10-21 Nouvelle association synergique pour le traitement de lésions profondes de la peau ou des muqueuses

Country Status (2)

Country Link
EP (1) EP2344173A1 (fr)
WO (1) WO2010045969A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1401083B1 (it) * 2010-07-27 2013-07-12 Pasquali S R L Composizione per il trattamento e la prevenzione dell'herpes simplex labiale.
IT1401895B1 (it) 2010-10-18 2013-08-28 Straccia Presidio farmacologico naturale per la prevenzione delle malattie infiammatorie del parodonto.
IT1402749B1 (it) * 2010-10-28 2013-09-18 Indena Spa Composizioni per il trattamento di ulcere periferiche di varia origine
EP2762146A1 (fr) * 2013-01-31 2014-08-06 Unigroup ApS Composition pour mal d'oreille
KR102190710B1 (ko) 2013-03-14 2020-12-14 마리 케이 인코포레이티드 화장품 조성물들
JP6392026B2 (ja) * 2014-08-19 2018-09-19 株式会社山田養蜂場本社 美白用組成物
CN104288409A (zh) * 2014-10-09 2015-01-21 苏珊珊 一种消炎止痒的中草药组合物及其制备方法
CN104435495A (zh) * 2014-10-25 2015-03-25 靳维荣 一种预防和治疗压疮病粉剂的制备方法
CN104644945B (zh) * 2015-02-06 2019-01-29 马汝逸 口疮消痛散以及制备方法
RU2580304C1 (ru) * 2015-02-26 2016-04-10 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" (ФБУН ГНЦ ВБ "Вектор") ПРОТИВОВИРУСНОЕ СРЕДСТВО НА ОСНОВЕ СУММЫ ФЛАВОНОИДОВ ИЗ Alchemilla vulgaris L.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3641220A1 (de) * 1986-12-03 1988-06-16 Christian Calarasu Arzneimittel zur behandlung von psoriasis oder neurodermatitis
ES2012104A6 (es) * 1988-06-28 1990-03-01 Perez Julio Tellez Procedimiento para la extraccion y aislamiento del principio activo regenerador epidermal de la mimosa tenuiflora y composicion cosmetica que lo contiene.
FR2674750B1 (fr) * 1991-04-03 1993-12-24 Synthelabo Extraits d'alchemille, leur preparation et leurs applications.
DE19712659C1 (de) * 1997-03-26 1998-08-20 Weber & Weber Gmbh Verwendung eines Extraktes von Alchemilla vulgaris
IT1320192B1 (it) * 2000-05-12 2003-11-26 Giovanni Summo Composizione terapeutica per la cura della psoriasi.
KR100431076B1 (ko) * 2003-06-16 2004-05-12 주식회사 코스메카코리아 천연 혼합 추출물을 함유하는 아토피 피부의 치유개선효과를 갖는 화장료

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2010045969A1 *

Also Published As

Publication number Publication date
WO2010045969A1 (fr) 2010-04-29

Similar Documents

Publication Publication Date Title
EP2344173A1 (fr) Nouvelle association synergique pour le traitement de lésions profondes de la peau ou des muqueuses
RU2640020C2 (ru) Композиция для местного применения, содержащая глицерин и танин
Firdous et al. Medicinal plants with wound healing potential
CN105833279B (zh) 皮肤多种损伤创面治疗的外用药物组合物及其制备方法
US9770475B2 (en) Compositions for the treatment of peripheral ulcers of various origins
CN109498605B (zh) 一种治疗妇科炎症的组合物及其在外用组合物中的应用
Pellenz et al. Healing activity of Stryphnodendron adstringens (Mart.), a Brazilian tannin-rich species: A review of the literature and a case series
Fontes et al. Bacterial cellulose/phytotherapic hydrogels as dressings for wound healing
Deka et al. Mechanism of action of wound healing activity of Calendula officinalis: a comprehensive review
RO128713B1 (ro) Unguent pentru tratamentul arsurilor şi plăgilor, cu acţiune complexă, realizat exclusiv din produse naturale
WO2020055135A2 (fr) Composition pour le traitement d'une plaie ou d'une cicatrice, comprenant un patch d'hydrogel
Soni et al. Effect of ethanolic extract of cinnamomum tamala leaves on wound healing in stz induced diabetes in rats
Ofori-Kwakye et al. Wound healing potential of methanol extract of Spathodea campanulata stem bark forumlated into a topical preparation
CN115721770B (zh) 一种止血组合物及其作为液体绷带的应用
CN109731040A (zh) 一种外伤修复组合物、制备方法及其应用
KR20010109042A (ko) 항염증 효과를 갖는 알로에 함유 습포제
Farzadinia et al. Healing effects of Pergularia tomentosa L., a native medicinal plant in Bushehr province, Iran on burn, in animal model.
CN103191163B (zh) 一种皮肤创面修复药物组合物
JP6538218B2 (ja) グリセロールとタンニンを含む局所適用のための組成物
KR20220011331A (ko) 아토피 피부염 개선용 화장료 조성물 및 그의 제조방법
Edula et al. Formulation and evaluation of wound healing activity of polyherbal gel
AU2013254342B2 (en) New compositions for the treatment of chronic ulcers
Almaamari Pharmacological effects and pharmaceutical dosage forms development of aloe vera
EP3806878B1 (fr) Compositions à base d'herbes médicinales pour le traitement de l'urolithiase et d'infections des voies urinaires
CN101584746B (zh) 伤口愈合的医药组合物及其制备方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110418

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20120124

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120605